Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of combined treatment with benazepril and spironolactone on diabetic nephropathy and serum levels of IL-6, CRP and TNF-α

Xiaoxing Duan, Liying Zhang, Xue Pan, Dongying Shi

Department of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia 010050, China;

For correspondence:- Dongying Shi Email: s90m6m@163.com

Accepted: 31 January 2022 Published: 28 February 2021

Citation: Duan X, Zhang L, Pan X, Shi D. Effect of combined treatment with benazepril and spironolactone on diabetic nephropathy and serum levels of IL-6, CRP and TNF-α. Trop J Pharm Res 2022; 21(2):341-347 doi: 10.4314/tjpr.v21i2.17

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the therapeutic effect of a combination of benazepril and spironolactone on diabetic nephropathy patients, and also to determine the influence of the combined treatment on serum IL-6, CRP and TNF-α.

Methods: 100 diabetic nephropathy patients admitted to The Affiliated Hospital of Inner Mongolia Medical University from April 2019 to October 2020 were randomly chosen and divided into groups E and F by drawing lots (n = 50 each). Group E received benazepril, while group F received a combined treatment of benazepril and spironolactone. Therapeutic efficacy, incidence of adverse drug reactions, and renal function after treatment, as well as IL-6, CRP and TNF-α levels in serum pre- and post-treatment, were determined. Fasting blood glucose (FBG) levels were also measured pre-treatment, and at 7 days and 14 days post-exposure to drugs.

Results: Therapeutic efficacy and renal functions were significantly better in group F than in group E, while post-treatment incidence of adverse drug reactions, and expression levels of CRP, IL-6, and TNF-α levels were significantly reduced in group F, relative to group E (p < 0.05). Following treatment, the inflammatory factor levels were decreased in both groups.

Conclusion: The combination of benazepril and spironolactone produces higher treatment effect in diabetic nephropathy patients than those that received benazepril only. The combined treatment is recommended in the management of diabetic nephropathy patients.

Keywords: Benazepril, Spironolactone, Diabetic nephropathy, Inflammatory factors, Fasting blood glucose